Steven Cohen’s Zevra Therapeutics ZVRA Stock Holding History

Steven Cohen’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,157,131	Closed	-$10.8M	–	4669
2026 Q1	$10.8M	Buy	+1,157,131	New	+$10.4M	0.01%	1192
2024 Q2	–	Sell	-90,802	Closed	-$527K	–	2542
2024 Q1	$527K	Buy	+90,802	New	+$558K	﹤0.01%	1633
2016 Q4	–	Sell	-23,944	Closed	-$1.72M	–	856
2016 Q3	$1.72M	Hold	23,944	–	–	0.01%	576
2016 Q2	$1.52M	Buy	23,944 +4,064	+20%	+$669K	0.01%	587
2016 Q1	$4.61M	Buy	+19,880	New	+$4.81M	0.04%	443

Other funds holding ZVRA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Steven Cohen's ZVRA Position: Q2 2026 in Review

Steven Cohen sold out of Zevra Therapeutics (ZVRA) in Q2 2026, closing a stake of 1,157,131 shares — an estimated $10.8M sold.

Steven Cohen first reported a position in ZVRA in Q1 2016 and held it in 5 quarters. The position peaked at $10.8M in Q1 2026. 156 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

Steven Cohen reported no remaining Zevra Therapeutics position as of Q2 2026 after selling out during the quarter.
Steven Cohen sold 1,157,131 Zevra Therapeutics shares in Q2 2026, an estimated $10.8M.
Steven Cohen first reported a position in Zevra Therapeutics in Q1 2016 and held it in 5 quarters.
Steven Cohen's Zevra Therapeutics position peaked at $10.8M in Q1 2026.
156 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.